Reducing Triglycerides News
- BioTrove Announces R&D Collaboration with Constellation Pharmaceuticals Tuesday, November 11, 2008 @ 10:06AMBioTrove, Inc. today announced it has formed a research collaboration with Constellation Pharmaceuticals in which Constellation will utilize BioTrove's RapidFire(R) Mass Spectrometry (RF-MS) system to accelerate development of novel therapeutics in the emerging field of epigenetics.
- To Your Health Tuesday, October 28, 2008 @ 5:21AM "Eat your broccoli -- it's good for you!" That's a refrain many of us remember hearing in childhood. And it may be one that we've passed on to our own children at the dinner table. Well guess what? Broccoli really is good for you.
- A diet that will win your heart Tuesday, October 28, 2008 @ 3:23AMWhen it comes to your heart, small is big. Small dietary changes can make a really big difference in reducing your risk for heart disease.
- ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed ... Monday, October 27, 2008 @ 8:00AM Results of two Phase III studies affirmed the clinical benefits of ACTEMRA -
- New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients Saturday, October 25, 2008 @ 8:00PM One-year study results showed improved physical function in patients treated with ACTEMRA -
- Orexigen(R) Therapeutics Reviews Significant Data Regarding Its Obesity Product Candidates Monday, October 6, 2008 @ 3:45PM Orexigen Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced that the company reviewed in an oral presentation at The Obesity Society Annual Scientific Meeting that the investigational drug, Empatic , demonstrated up to 15% reduction in body weight of healthy obese people who completed 48-weeks ...
- Novel Short-Term Weight-Loss Approach Works Long-Term for Type 2 Diabetes Tuesday, September 2, 2008 @ 3:28PMA study by researchers from the Joslin Diabetes Center has shown for the first time that more than half of patients with type 2 diabetes who enrolled in a novel short-term weight management program were able to maintain the weight loss they achieved during the program on their own long-term.
- New Survey Among European Cardiologists Points to a G. Tuesday, September 2, 2008 @ 1:37PMCardiologists in Europe agree that reducing LDL-cholesterol (LDL-C or "bad" cholesterol) levels is the most important factor in treating dyslipidemia (abnormal blood lipids) and reducing the risk of a cardiovascular event.
- Q&A: Fitness advice on reducing midsection Monday, August 18, 2008 @ 3:15PMLosing weight around the waistline is a goal for many people. There are numerous misconceptions related to how to best reduce body fat in this area, probably due to infomercials claiming 6-pack abs in minutes a day, supplements suggesting fast and easy weight loss, and a mountain of misinformation related to diet.
- Nation/World Roundup for August 12 Tuesday, August 12, 2008 @ 2:58PMMOSCOW (AP) — Russian President Dmitri Medvedev ordered a halt to military action in Georgia Tuesday, saying it had punished Georgia and brought security for civilians and Russian peacekeepers in the breakaway South Ossetia region.
- PACKING POWER INTO PRODUCTS Sunday, August 10, 2008 @ 4:25AMThe letter P, to some ears, stands for power. So it's no coincidence that a plethora of drugs - from Prozac to Provenge - feature this brawny consonant.
- Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and ... Tuesday, August 5, 2008 @ 10:26PMÇѹ·Õè 6 ÊÔ§ËÒ¤Á 2551 09:25 ¹. HIV-Infected Women and Non-Whites New to Antiretroviral Therapy Respond Similarly to Men and Whites Initial treatment regimens containing once-daily or twice-daily dosing of Abbott's (NYSE: ABT) protease inhibitor Kaletra(R) (lopinavir/ritonavir) tablet provided similar results for controlling the virus (reducing the amount of HIV-1) and improving the immune system ...
- Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and ... Tuesday, August 5, 2008 @ 9:51PMATTENTION EDITOR, GENERAL DESK
- Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and ... Tuesday, August 5, 2008 @ 9:14PMMexico City (ots/PRNewswire) - - HIV-Infected Women and Non-Whites New to Antiretroviral Therapy Respond Similarly to Men and Whites Initial treatment regimens containing once-daily or twice-daily dosing of Abbott's (NYSE: ...
- Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and ... Tuesday, August 5, 2008 @ 3:51PMMexico City (ots/PRNewswire) - - HIV-Infected Women and Non-Whites New to Antiretroviral Therapy Respond Similarly to Men and Whites Initial treatment ...
- Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and ... Tuesday, August 5, 2008 @ 3:20PM Initial treatment regimens containing once-daily or twice-daily dosing of Abbott's protease inhibitor Kaletra® tablet provided similar results for controlling the virus and improving the immune system in women compared to men and in non-whites compared to whites, according to 48-week data presented by Abbott today at the XVII International AIDS Conference .
- Karo Bio Announces Successful Phase II Study with Eprotirome in Combination with Statin Monday, August 4, 2008 @ 2:54AM STOCKHOLM, Sweden----Eprotirome is a novel, selective, thyroid hormone receptor agonist, developed for treatment of dyslipidemia. To explore the potential for eprotirome as an add-on to standard statin treatment, Karo Bio conducted a phase IIb placebo controlled, randomized, double blind, 12 week study in 189 patients, each with high levels of serum cholesterol.
- FDA Advisory Committee Recommends Approval Of Actemra For The Treatment Of Rheumatoid Arthritis Thursday, July 31, 2008 @ 5:11AMRoche announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) by a near unanimous (10-1) vote recommended approval of Actemra (tocilizumab), a novel interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody, for reducing the signs and symptoms in adults with moderate to severe rheumatoid arthritis (RA).
- No Evidence Yet On Whether Diet Alone Can Control Type 2 Diabetes Thursday, July 17, 2008 @ 4:08AMDespite strong evidence that type 2 diabetes can be prevented or at least delayed by a combination of lifestyle changes and good dietary advice, a team of Cochrane Researchers found that there is no indication whether dietary advice alone can prevent the disease. Type 2 diabetes is very common and the number of people affected is increasing.
- Diet alone cannot control type 2 diabetes Wednesday, July 16, 2008 @ 10:59PMDespite strong evidence that type 2 diabetes can be prevented or at least delayed by a combination of lifestyle changes and good dietary advice, a team of Cochrane Researchers found that there is no indication whether dietary advice alone can prevent the disease.
- Spending On Cholesterol Reducing Statins More Than Doubles In Just Five Years, USA Wednesday, June 25, 2008 @ 3:16PMSpending on statins, drugs used to reduce artery-clogging cholesterol, increased 156 percent between 2000 and 2005, according to the latest News and Numbers from the federal Agency for Healthcare Research and Quality.
- Drug for many reasons Saturday, May 24, 2008 @ 8:14PMAn oral anti-diabetic drug has been shown to reduce the clogging of arteries and lowers other risk factors as well.
- Anti Inflammatory Medication May Treat Type 2 Diabetes Thursday, May 22, 2008 @ 7:13AMResearchers at the Joslin Diabetes Center who reported earlier this year that an inexpensive, non-steroidal anti-inflammatory drug called salsalate might prevent type 2 diabetes are now reporting that the drug may also be beneficial in the treatment of the disease.
- Arthritis drug may help Type 2 diabetes patients Thursday, May 22, 2008 @ 4:56AMWashington, May 22 : Researchers at the Joslin Diabetes Centre have found that a drug used to treat arthritis can actually help in treating type 2 diabetes.
- Medicure Announces Presentation of Phase II Matched Results at Cardiovascular Conference Wednesday, April 16, 2008 @ 7:00AM Medicure Inc.(AMEX: MCU), a cardiovascular-focused biopharmaceutical company, today announced that the positive results from the Phase II MATCHED study, which evaluated the combination of MC-1 and lisinopril in patients with coexisting type II diabetes and hypertension, will be presented today at the Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2008 in Atlanta, GA.
- Studies vary on cinnamon’s effects on diabetes control Wednesday, April 16, 2008 @ 1:13AM Q: Isn’t it true that cinnamon is helpful in controlling diabetes and cholesterol?
- Reducing daily exercise soon takes its toll --- HealthandAge Thursday, April 10, 2008 @ 9:50AMLittle is known of how reduced exercise affects metabolism. In a study on healthy young volunteers, cutting down the daily number of steps taken had a surprisingly rapid impact on insulin sensitivity and deposition of abdominal fat, suggesting it is vital to keep up a regular routine.
- eFoodSafety Launches Cinnechol(TM), An All-Natural Alternative To Conventional Cholesterol Drugs Wednesday, April 9, 2008 @ 6:01PMeFoodSafety.com (OTCBB: EFSF, http://www.efoodsafety.com), a researcher, developer, and marketer of whole food nutraceutical products, has launched an all-natural supplement, called Cinnechol™ (http://www.cinnechol.com), that offers a complementary and/or alternative solution to traditional cholesterol drugs.
- In Conjunction with Release of Study Recommending Omega-3 for Cardioprotection, NourishLife Announces Free Sample ... Sunday, April 6, 2008 @ 7:59AMStudy proves that omega-3 can reduce cardiovascular events & triglyceride levels, and Nourishlife responds by adding free samples to its awareness campaign. [PR.com - April 05, 2008]
- Abbott may gain as rivals feel pain Thursday, April 3, 2008 @ 8:29AMIf doctors take the advice of some leading cardiologists to move away from prescription cholesterol treatments Vytorin and Zetia, Abbott Laboratories ' developing franchise to combat heart disease could get a boost.
- Doctors Leery Of Cholesterol Drugs After Study Monday, March 31, 2008 @ 9:19PMFull results of a failed trial on Vytorin, a medicine taken by millions of Americans to lower cholesterol, left doctors stunned that the drug did not improve heart disease even though it worked as intended to lower three key risk factors.
- Study: Vytorin, Zetia don't fight heart disease Monday, March 31, 2008 @ 8:05PMFull results of a failed trial on Vytorin, a medicine taken by millions of people to lower cholesterol, found the drug did not improve heart disease even though it worked as intended to lower three key risk factors. Use of Vytorin an ...
- Doctors wary after cholesterol drug flop Monday, March 31, 2008 @ 7:25PMLeading doctors urged a return to older, tried-and-true treatments for high cholesterol after hearing full results Sunday of a failed trial of Vytorin. Millions of Americans already take the drug or one of its components, Zetia. But doctors were stunned to learn that Vytorin failed to improve heart disease even though it worked as intended to reduce three key risk factors. "People need to turn ...
- Doctors leery of Vytorin, Zetia Monday, March 31, 2008 @ 4:13PMDoctors concerned over some cholesterol drugs after hearing results on Sunday.
- A Backlash Against Vytorin? Monday, March 31, 2008 @ 1:57PMAnxiety is deepening among researchers about the cholesterol drugs Zetia and Vytorin. Bad news for Merck and Schering-Plough.
- Doctors leery of cholesterol drugs Vytorin, Zetia after key study flops Monday, March 31, 2008 @ 1:08PMZetia and Vytorin have racked up $5 billion in sales despite limited proof of benefit
- Patients Treated with Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE(TM)) Reported ... Monday, March 31, 2008 @ 12:33PMPatients with dyslipidemia treated with CORDAPTIVE(TM) (extended release niacin/laropiprant) reported significantly less flushing and significantly fewer discontinuations due to flushing than patients treated with Niaspan(TM) (Abbott). Niacin is a proven lipid-modifying agent; however, a major barrier to its use is the side effect of flushing. These Phase III study results were presented today ...
- Offices are starting to look like wellness centers Monday, February 25, 2008 @ 7:25AMRemember the days of junior high gym class? You quickly change into your gym clothes, throw on a ratty old T-shirt and Umbro shorts and hope no one pulls the fire alarm.
- GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients ... Monday, February 25, 2008 @ 6:25AMGTx, Inc. (NASDAQ:GTXI) today announced Phase III clinical data for toremifene citrate 80 mg, the Company's investigational therapy for the treatment of multiple side effects of androgen deprivation therapy (ADT) for advanced prostate cancer. Results show that toremifene citrate 80 mg reduced vertebral fractures and met other key endpoints, including bone mineral density, lipid profiles, and ...
- GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients ... Monday, February 25, 2008 @ 6:00AM MEMPHIS, Tenn.----GTx, Inc. today announced Phase III clinical data for toremifene citrate 80 mg, the Company's investigational therapy for the treatment of multiple side effects of androgen deprivation therapy for advanced prostate cancer.
- Top Reasons Why Pets Make Life Whole Wednesday, February 20, 2008 @ 6:03PMMany of us have heard the benefits of owning a pet. Some benefits are obvious and some are not so obvious. Here are my top ten reasons for owning a pet:
- Eating Red May Prevent Dropping Dead Monday, February 18, 2008 @ 2:01AMEating red fruits and vegetables may help reduce inflammation which in turn cuts the risk of heart attack, a U.S. doctor says.
- SourceOne develops heart health platform Thursday, February 14, 2008 @ 1:29PMThe company, which partners with manufacturers and suppliers worldwide to market "science-driven" products, said its heart-health platform - branded Cholesstrinol - will help leverage the scientific basis of its heart health ingredients, and position them for long-term success.
- GTx: A Compelling Biotech Tuesday, February 12, 2008 @ 9:46AMS&P says the company's lead drug candidate, Acapodene, represents a "significant opportunity" in the treatment of prostate cancer
- Diabetics more at risk for heart health problems Monday, February 11, 2008 @ 5:45AMIf you have diabetes, your risk of having a heart attack is the same as a non-diabetic who has had a heart attack. So make heart health a priority. What things can and should you do? First, make sure you have a doctor.
- Sitting ducks Saturday, February 9, 2008 @ 8:22AMSITTING down is about to join smoking and junk food on the list of vices that increase your risk of diabetes and heart disease.
- Dense fiber fills dieting bill Tuesday, February 5, 2008 @ 2:08AMI've heard that something called glucomannan can help you lose weight. What exactly is this stuff? How does it work?
- Celebrate American Heart Month by Eating Red Monday, February 4, 2008 @ 8:00AM Go red" or "wear red" have become universal mantras for promoting heart-health during February, American Heart Month.
- Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy Thursday, January 31, 2008 @ 8:00AM Clinical trial results from a new cholesterol-fighting drug combination point to the need for more detailed cholesterol testing, including direct measurement of LDL and other lipids.
- Celebrate American Heart Month By Eating Red Wednesday, January 30, 2008 @ 7:15AM"Go red" or "wear red" have become universal mantras for promoting heart-health during February, American Heart Month. But health and nutrition experts say we should also be eating red to protect our hearts. Americans are encouraged to discover the power of eating heart-healthy red foods during the first-ever National Eat Red Week, Feb. 4-10.
